Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)-Reference-Cited by-同舟云学术

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)

Published:2018-05 Issue:5 Volume:78 Page:863-871.e11
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Simpson Eric L.,Flohr Carsten,Eichenfield Lawrence F.,Bieber Thomas,Sofen Howard,Taïeb Alain,Owen Ryan,Putnam Wendy,Castro Marcela,DeBusk Kendra,Lin Chin-Yu,Voulgari Athina,Yen Karl,Omachi Theodore A.

Publisher

Elsevier BV

Subject

Dermatology

Reference34 articles.

1. Epidemiology of atopic dermatitis: a review;DaVeiga;Allergy Asthma Proc,2012

2. A practical overview of pediatric atopic dermatitis, part 1: epidemiology and pathogenesis;Silverberg;Cutis,2016

3. How epidemiology has challenged 3 prevailing concepts about atopic dermatitis;Williams;J Allergy Clin Immunol,2006

4. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults;Simpson;J Am Acad Dermatol,2016

5. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies;Eichenfield;J Am Acad Dermatol,2014

Cited by 277 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic Immunomodulatory Treatments for Atopic Dermatitis;JAMA Dermatology;2024-07-17

2. Emerging Systemic Treatment Options in Atopic Dermatitis;Balkan Medical Journal;2024-07-05

3. Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis;Dermatology and Therapy;2024-06-26

4. Monoclonal Antibodies: Current Advancements and Future Potential for Atopic Dermatitis Therapy;Current Pharmaceutical Biotechnology;2024-06-25

5. Monoclonal antibodies for moderate-to-severe atopic dermatitis: a look at phase III and beyond;Expert Opinion on Biological Therapy;2024-06-02